The Indian BioScience industry witnessed tremendous highs and lows in 2013. Specifically, the pharmaceutical industry took most of the beating, owing to regulatory woes within the country and import bans from foreign bodies.
However, in terms of new innovation and products developed, India made many heads turn in the global market towards itself. Major collaboration and acquisitions were a continuous integral part of many Indian companies.
Here is an exclusive sneek-peek of the significant events in 2013:
Being set up at the cost of Rs 2,035 crore, the National Cancer Institute (NCI) is expected to cater to requirements in northern India. This is a landmark step in the arena of cancer research in the country and shall lessen the deficit of tertiary cancer care in the Northern region. Cancer is emerging as a major public health concern in India, where every year 11 lakhs new cases are diagnosed, with a mortality rate of 5.5 lakhs per year.
While the Bt brinjal issue in India continues to remain tangled in the political and legal systems, Bangladeshis have decided to take the plunge. It may sound positive for the industry, activists feel otherwise. The top regulatory authority in Bangladesh, the National Committee on Biosafety (NCB), has given its approval in November, 2013, to the commercial cultivation of the Bt brinjal, making it the country first in South Asia to allow the entry of any edible genetically modified (GM) crop in its market.